Purchased Common Stock and Warrants in the 2025 private placement (2025 PIPE financing)
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Margaret Alexander
Also a director
President, Chief Executive Officer and Director
|
45 | Not stated | $1,022,272 | |
|
Charles Carter
Chief Financial Officer
Title from the Form 8-K dated Jul 6, 2026
|
Not stated | Not stated | Not reported | |
|
Jeremy M. Levin
Executive Chairman of the Board
|
72 | Not stated | $1,934,699 | |
|
Jeffrey Rona
Chief Business and Financial Officer
|
57 |
Since 2021
5 years
|
$969,164 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 27, 2026 · updated by the 8-K of Jun 3, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Levin
Board chair
|
Not stated | Not stated | Not independent | None stated | None stated | Not stated | |
|
Margaret Alexander
CEO
|
45 |
2026
this year
|
Not independent | None stated | None stated | Paid as CEO | |
|
Bart Friedman
Lead independent director
|
81 |
2015
11 years
|
Not stated |
Audit
|
None stated | Not stated | |
|
Barbara Duncan
|
61 |
2017
9 years
|
Not stated |
Nominating and Corporate Governance
|
Halozyme Therapeutics, Inc., Atea Pharmaceuticals, Inc., Fusion Pharmaceuticals Inc. | $86,266 | |
|
Stelios Papadopoulos
|
77 |
2025
1 year
|
Not stated |
Audit
Compensation
|
Exelixis, Inc. | $88,906 | |
|
Kevin Fitzgerald
|
58 |
2021
5 years
|
Not stated |
Nominating and Corporate Governance
|
None stated | $69,940 | |
|
Karen Bernstein
|
Not stated | Not stated | Not stated | None stated | None stated | $89,940 | |
|
Anna Greka
Joined Jun 15, 2026
|
- | - | - |
Compensation Committee
Science and Technology Committee
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Purchased Common Stock and Warrants in the 2025 private placement (2025 PIPE financing)
Purchased Common Stock and Warrants in the 2025 private placement (2025 PIPE financing)
Purchased Common Stock and Pre-Funded Warrants in the 2026 private placement (2026 PIPE)
Loading...